vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Freshworks Inc. (FRSH). Click either name above to swap in a different company.
Freshworks Inc. is the larger business by last-quarter revenue ($228.6M vs $183.1M, roughly 1.2× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -2.1%, a 15.4% gap on every dollar of revenue. On growth, Freshworks Inc. posted the faster year-over-year revenue change (16.5% vs -1.8%). Over the past eight quarters, Freshworks Inc.'s revenue compounded faster (14.6% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Freshworks Inc. is a cloud-based software-as-a-service company, founded in 2010 in Chennai, India. The company provides cloud-based tools for customer relationship management (CRM), IT service management (ITSM), and e-commerce marketing.
AMPH vs FRSH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $228.6M |
| Net Profit | $24.4M | $-4.8M |
| Gross Margin | 46.8% | 84.8% |
| Operating Margin | 19.4% | 11.6% |
| Net Margin | 13.3% | -2.1% |
| Revenue YoY | -1.8% | 16.5% |
| Net Profit YoY | -35.7% | -268.9% |
| EPS (diluted) | $0.51 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $228.6M | ||
| Q4 25 | $183.1M | $222.7M | ||
| Q3 25 | $191.8M | $215.1M | ||
| Q2 25 | $174.4M | $204.7M | ||
| Q1 25 | $170.5M | $196.3M | ||
| Q4 24 | $186.5M | $194.6M | ||
| Q3 24 | $191.2M | $186.6M | ||
| Q2 24 | $182.4M | $174.1M |
| Q1 26 | — | $-4.8M | ||
| Q4 25 | $24.4M | $191.4M | ||
| Q3 25 | $17.4M | $-4.7M | ||
| Q2 25 | $31.0M | $-1.7M | ||
| Q1 25 | $25.3M | $-1.3M | ||
| Q4 24 | $38.0M | $-21.9M | ||
| Q3 24 | $40.4M | $-30.0M | ||
| Q2 24 | $37.9M | $-20.2M |
| Q1 26 | — | 84.8% | ||
| Q4 25 | 46.8% | 85.6% | ||
| Q3 25 | 51.4% | 84.7% | ||
| Q2 25 | 49.6% | 84.8% | ||
| Q1 25 | 50.0% | 84.8% | ||
| Q4 24 | 46.5% | 84.9% | ||
| Q3 24 | 53.3% | 84.0% | ||
| Q2 24 | 52.2% | 83.8% |
| Q1 26 | — | 11.6% | ||
| Q4 25 | 19.4% | 17.8% | ||
| Q3 25 | 13.2% | -3.5% | ||
| Q2 25 | 24.2% | -4.2% | ||
| Q1 25 | 21.9% | -5.3% | ||
| Q4 24 | 24.2% | -12.2% | ||
| Q3 24 | 29.8% | -20.8% | ||
| Q2 24 | 30.3% | -25.1% |
| Q1 26 | — | -2.1% | ||
| Q4 25 | 13.3% | 86.0% | ||
| Q3 25 | 9.0% | -2.2% | ||
| Q2 25 | 17.8% | -0.8% | ||
| Q1 25 | 14.8% | -0.7% | ||
| Q4 24 | 20.4% | -11.3% | ||
| Q3 24 | 21.1% | -16.1% | ||
| Q2 24 | 20.8% | -11.6% |
| Q1 26 | — | $-0.02 | ||
| Q4 25 | $0.51 | $0.66 | ||
| Q3 25 | $0.37 | $-0.02 | ||
| Q2 25 | $0.64 | $-0.01 | ||
| Q1 25 | $0.51 | $0.00 | ||
| Q4 24 | $0.74 | $-0.07 | ||
| Q3 24 | $0.78 | $-0.10 | ||
| Q2 24 | $0.73 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $548.2M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $1.0B |
| Total Assets | $1.6B | $1.6B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $548.2M | ||
| Q4 25 | $282.8M | $781.4M | ||
| Q3 25 | $276.2M | $813.2M | ||
| Q2 25 | $231.8M | $926.2M | ||
| Q1 25 | $236.9M | $995.3M | ||
| Q4 24 | $221.6M | $1.1B | ||
| Q3 24 | $250.5M | $1.1B | ||
| Q2 24 | $217.8M | $1.0B |
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
| Q1 26 | — | $1.0B | ||
| Q4 25 | $788.8M | $1.0B | ||
| Q3 25 | $776.7M | $851.5M | ||
| Q2 25 | $757.5M | $984.6M | ||
| Q1 25 | $751.3M | $1.1B | ||
| Q4 24 | $732.3M | $1.1B | ||
| Q3 24 | $727.7M | $1.1B | ||
| Q2 24 | $713.3M | $1.1B |
| Q1 26 | — | $1.6B | ||
| Q4 25 | $1.6B | $1.6B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.5B | ||
| Q4 24 | $1.6B | $1.6B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.5B | $1.5B |
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $62.4M |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $62.4M | ||
| Q4 25 | $32.9M | $62.3M | ||
| Q3 25 | $52.6M | $63.5M | ||
| Q2 25 | $35.6M | $58.6M | ||
| Q1 25 | $35.1M | $58.0M | ||
| Q4 24 | $29.0M | $41.4M | ||
| Q3 24 | $60.0M | $42.3M | ||
| Q2 24 | $69.1M | $36.3M |
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $60.1M | ||
| Q3 25 | $47.2M | $61.7M | ||
| Q2 25 | $25.0M | $58.2M | ||
| Q1 25 | $24.4M | $56.7M | ||
| Q4 24 | $16.6M | $36.3M | ||
| Q3 24 | $46.2M | $41.3M | ||
| Q2 24 | $63.1M | $34.0M |
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 27.0% | ||
| Q3 25 | 24.6% | 28.7% | ||
| Q2 25 | 14.3% | 28.4% | ||
| Q1 25 | 14.3% | 28.9% | ||
| Q4 24 | 8.9% | 18.7% | ||
| Q3 24 | 24.1% | 22.1% | ||
| Q2 24 | 34.6% | 19.5% |
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 1.0% | ||
| Q3 25 | 2.8% | 0.8% | ||
| Q2 25 | 6.1% | 0.2% | ||
| Q1 25 | 6.3% | 0.7% | ||
| Q4 24 | 6.7% | 2.6% | ||
| Q3 24 | 7.2% | 0.6% | ||
| Q2 24 | 3.3% | 1.3% |
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 0.33× | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
FRSH
Segment breakdown not available.
